RARE Ultragenyx Pharmaceutical delivers 202 percent year over year revenue growth shares tick modestly higher post earnings Investar ISTR Stock Deal Activity Overhead Buying 20260424 SJM The JM reports 67 yearoveryear revenue growth but narrowly misses EPS estimates shares drop 078 today FFAI Faraday posts narrower Q4 2025 loss than analyst forecasts shares fall 20 percent amid investor disappointment The opportunity most miss about EHang EH Market Focus 20260511